Dr. Andrew Cuthbertson, BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO, has been the Chief Scientific officer and Director of R&D at CSL Ltd. since 2000. Dr. Cuthbertson serves as Chief Scientific Officer of CSL Behring LLC and has been its R&D Director since March 2000, where he is responsible for the global operations of Research and Development (R&D). Dr. Cuthbertson manages an internal R&D budget of over $350m and a global R&D organization of 800 scientists. He is responsible for crafting the global R&D strategy for CSL. Dr. Cuthbertson joined CSL Behring in 1997 as Research Director. Dr. Cuthbertson served as Group Chief Scientist of CSL Ltd. Dr. Cuthbertson trained for five years in molecular biology research as a staff Member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He spent seven years at Genentech, Inc. in San Francisco and worked on anti-VEGF therapy for age related macular degeneration. Dr. Cuthbertson has been a Director of Zenyth Therapeutics Pty Ltd since November 2006. He has a keen interest in biopharmaceutical drug development. He completed medical training at the University of Melbourne and a Ph.D. in Immunology at the Walter and Eliza Hall Institute in Australia. Dr. Andrew Cuthbertson, BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO, has been the Chief Scientific officer and Director of R&D at CSL Ltd. since 2000. Dr. Cuthbertson serves as Chief Scientific Officer of CSL Behring LLC and has been its R&D Director since March 2000, where he is responsible for the global operations of Research and Development (R&D). Dr. Cuthbertson manages an internal R&D budget of over $350m and a global R&D organization of 800 scientists. He is responsible for crafting the global R&D strategy for CSL. Dr. Cuthbertson joined CSL Behring in 1997 as Research Director. Dr. Cuthbertson served as Group Chief Scientist of CSL Ltd. Dr. Cuthbertson trained for five years in molecular biology research as a staff Member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He spent seven years at Genentech, Inc. in San Francisco and worked on anti-VEGF therapy for age related macular degeneration. Dr. Cuthbertson has been a Director of Zenyth Therapeutics Pty Ltd since November 2006. He has a keen interest in biopharmaceutical drug development. He completed medical training at the University of Melbourne and a Ph.D. in Immunology at the Walter and Eliza Hall Institute in Australia.

Research and Development